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One Giant Leap
For Damage Control Orthopaedics
LONDON • ENGLAND
To continue to provide expert and timely care, orthopaedic surgeons need to improve the evidence base and change the shape and size of the workforce, according to a presenter at the 15th EFORT Congress -a combined programme in partnership with the BOA.
"The wind of change is here and we must change, I believe. If we don't take the leadership and change, others such as politicians and mangers will. They will do it in a way that is unacceptable and unpalatable to us and actually I do not believe it will benefi t our patients," said Timothy Briggs, MBBS(Hons), MChOrth, FRCS(Ed), FRCS(Eng), at a 5 June symposium on international health care.
He said an increased demand for orthopaedic services, an ageing population who is living longer, a decreasing workforce and obesity have added to the health care burden around the world. In 1950, there were 856 million people older than age 60 years in the world. By 2050, there will be more than 2 billion people older than 60 years.
The annual budget in the United Kingdom for musculoskeletal disease is £10 billion, he said. Overall, 25% of surgical interventions in the secondary care sector are for musculoskeletal disease.
"We are big players in the game because we are 33% of the surgical workforce," Briggs said.
The world debt is $52 trillion as of mid-March 2014 and while GDP spending varies around the world, governments will prioritise spending. In the United Kingdom, he said 70 of 250 hospitals were in fi nancial defi cit at the end of the last fi nancial year. Despite an increase of 1.91%, they actually needed an increase of 4.6% to stay neutral. He said the NHS will be underfunded by billions in 4 years and orthopaedic surgeons will have to get used to tariff defl ation. Additionally, if orthopaedic surgeons don't address the challenge, general practitioners will continue to be under pressure not to refer patients for orthopaedic care. "We can no longer hold our head in the sand." he said.
Because response assessment after neoadjuvant therapy is not yet standardised for patients with localised, high-grade soft tissue sarcoma, investigators researched tumour response following two kinds of neoadjuvant treatment and found mitotic count and the amount of viable tumour were factors that correlated with tumour prognosis.
Dimosthenis Andreou, MD, will present the results of the single-centre retrospective study on Friday, 6 June.
Andreou said in an interview prior to the EFORT Congress -a combined programme in partnership with the BOA that he and his colleagues were interested in fi nding any differences in disease-specifi c survival (DSS) and event-free survival (EFS) in the study cohort based on mitotic count (MC) and the amount of viable tumour (VT).
"Our results are promising. Our study shows that the mitotic count after treatment can be used to separate patients into distinct prognostic groups," Andreou said.
From 2001 to 2011, a total of 118 patients underwent the combined treatment approach of neoadjuvant regional chemotherapy -isolated limb perfusion (ILP; 61 patients) or systemic chemotherapy (SC; 57 patients) followed up with surgical resection with intent to cure their localised, high-grade soft tissue sarcomas.
Median follow-up was 44 months in all patients and 56 months in survivors. The fi ndings were based on the analysis of sarcoma specimens obtained during surgical resection done after either SC or ILP.
The investigators found that when the amount of VT was less than 10% following SC, patients had a 94% DSS at 5 years. The DSS was 61% at 5 years when the amount of VT was equal to or higher than 10% in these patients.
DSS and EFS did not correlate, however, with the amount of VT after ILP, according to the results.
The MC results showed a signifi cantly lower DSS and EFS in patients after SC with an MC that was equal to or higher than 20/10 high power fi elds (HPF) compared to that in patients with a MC less than 20/10 HPF. In patients with a lower MC, the DSS was 84% at 5 years compared to a DSS of 33% in patients with a higher MC.
"Following ILP the survival benefi t was more pronounced for patients with a MC less than 10/10 HPF who had a signifi cantly higher DSS and EFS than patients with a MC equal to or higher than 10/10 HPF," Andreou and colleagues wrote.
Andreou said, "For patients with isolated limb perfusion, we found the MC was a means to discriminate between patients with a good prognosis and patients with a poor prognosis."
These fi ndings must be interpreted correctly, he said, noting different chemotherapy plans could lead to a different correlation between mitotic count and prognosis. The vast majority of samples the investigators assessed were from undifferentiated sarcomas.
Reference:
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Soft tissue sarcoma prognosis correlates with mitotic count, amount of viable tumour after neoadjuvant treatment
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Surgeons must consider a patient's knee pain and the risk of disease progression when choosing unicompartmental, bicompartmental or total knee arthroplasty as an appropriate treatment, according to presenters during a debate forum session.
David W. Murray, MD, PhD; Sebastien Parratte, MD, PhD; and Jan Victor, MD, PhD, discussed the merits of the multiple compartment procedures compared to unicompartmental arthroplasty. They defended unicompartmental knee arthroplasty (UKA), bicompartmental knee arthroplasty and total knee arthroplasty (TKA), respectively, at the 15th EFORT Congress -a combined programme in partnership with the BOA.
In general, they agreed there is a need for each of these procedures based on the indications.
"UKA deserves a place in the toolbox of treating degenerative arthritis of the knee but the main enigma is nailing your indications and that's your job," Victor said.
"TKA has a better survivorship than UKA. That is clear in our minds. I think UKA is a logical operation that deserves its place with patient selection, in my view, as the weakest part of the procedure," he said.
Murray argued that TKA is diffi cult to revise and defended UKA with data from national joint replacement registers that support the use of the prosthesis.
"Anterior knee pain does not compromise the procedure," said Murray, who also reviewed the merits of fi xed vs. mobile-bearing UKA procedures.
He defended the arguments that revision rates are high with UKA. A study conducted by Murray and colleagues demonstrated that most surgeons do fi ve to 10 UKAs annually. "The optimum results occur if about 50% of the annual knee replacements are 'unis, '" Murray said.
Furthermore, he said complications are fewer with UKA than TKA.
With bicompartmental knee arthroplasty surgeons can better manage rotation according to their preferences and the patient's needs, according to Parratte.
"You can manage size easily and you can manage the femorotibial joint line without compromise," he said.
Ultimately, the use of bicompartmental knee arthroplasty vs. UKA comes down to management of the patellofemoral joint.
"The patellofemoral joint may be painful for the patient…that is my concern," Parratte said. All content herein is protected by copyright, trademarks and other intellectual property rights owned by or licensed to Biomet Inc. or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Biomet. 
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EFORT will head to Prague for the 16th EFORT Congress in May 2015.
The EFORT education committee, chaired by Enric Caceres, MD, chairman of the EFORT Scientifi c Committee, with ongoing support from the Specialist Societies, have created an exceptional programme covering differing topics from basic research to areas within daily practice of orthopaedics and trauma. The theme of the meeting is musculoskeletal infection.
"Infection was chosen for the subject of relevance for the Prague congress," Caceres said. "Of all the complications that occur in orthopaedic surgery, these types of infections are most costly. For example, a prosthetic knee may affect revenue for several months -this is the main reason we chose this topic. Many of these activities in Prague will be shared with the European Bone & Joint Infection Society."
The planned programme of the meet-ing will include topics on the treatment of extracapsular proximal femoral fractures, spine surgery safety, complex injuries around the elbow, post-traumatic hand soft tissue defects and dual the indication and limitations of mobility in THA.
In addition, lectures will be given by renowned international experts on general orthopaedics on topics that include RSA studies in implant research, economics of orthopaedic infections and current issues in tribology. Caceres said a focus on paediatrics is also planned, dealing with knee injuries in children.
"The EFORT Congress is chosen within 4 or more years in advance of the meeting," Caceres said. "We try to diversify the venues serving the different locations of the countries comprising EFORT. Prague is a great opportunity to share knowledge amoung countries in North, South and Central Europe and Eastern Europe. It also has a great tourist attraction and we hope that the conference is a great success."
We look forward to seeing you at the 16th EFORT Congress.
EFORT heads to Prague for 2015 Congress
A classic debate about cemented vs. uncemented total hip arthroplasty held at the 15th EFORT Congress -a combined programme in partnership with the BOA highlighted several points of contention that are often argued about concerning these two methods of total hip arthroplasty (THA) fi xation, including long-term survivorship, issues of anatomic restoration and revision and implantation, as well as thigh pain.
"With cement in such widespread use around the world in hundreds of thousands of databases per year, the question is surely not whether cement brings advantages, it is how cement brings advantages to those hip replacements," said Jonathan R. Howell, MBBS, MSc, FRCS(T&Ortho), one of four participants in the symposium, which was moderated by John Timperley, MBChB, FRCS(Ed), DPhil(Oxon), of Exeter, United Kingdom.
Howell and Henrik Malchau, MD, PhD, spoke in favour of the motion that there are advantages to fi xation of THA using cement, and Michel P. Bonnin, MD, of Lyon, France, and Richard Field, PhD, FRCS, FRCS(Orth), of Carshalton, United Kingdom, argued against the use of cement to fi x THA implants.
Bonnin gave 10 reasons why orthopaedic surgeons should perform cementless THA, which included the fact that hydroxyapatite on the surface of cementless THA prostheses helps facilitate bone bridging that promotes osteointegration and better implant stability.
He discussed his experience with the DePuy Synthes Corail Total Hip System, which he noted has success based on a compaction broaching concept that addresses the bioactive part of the bone.
"When we have primary stability, it is fi nished. It is done, but you have to respect the tips and tricks to have a good result. You must have good preoperative planning, use progressive size of the broaches, gentle compaction. You stop when it's stable. You have to use a reamer only if you have a very narrow canal," Bonnin said.
"In the primary diffi cult situation, I think uncemented stems are easier to use and are better," he said.
According to Howell, cemented THA provides better restoration of the original hip anatomy and allows for intraoperative correction of inclination of the acetabular cup and of version.
"We've got to restore our patients' offset," Howell said.
This, he noted, is essential to a patient's gait and function, and the ability of the surgeon to restore leg length, which are areas that support improved patient satisfaction after primary THA.
"After 30 years' experience with cemented and uncemented hip replacement, I am sure that the general public would expect our profession to have a very, very clear idea of which form of fi xation is better at restoring anatomy. But, there is virtually nothing in the literature on this issue. However, what is written in the literature favours cemented fi xation," Howell said.
The health economics are also better with cemented THA due to the reported potential reduction in revision rates at 5 postoperative years, he said.
Reference:
Symposium: Cemented versus cementless hip: There are advantages to fi xation using cement. Presented at: 15th EFORT Congress -a combined programme in partnership with the BOA; 4-6 June, 2014; London. 
Debaters argue for and against primary cemented THA, cite outcomes, revision issues
Jonathan R. Howell Michel P. Bonnin
Data on cemented and uncemented total hip arthroplasty in registries and the literature may guide surgeons in choosing between fi xation types.
EFORT General Assembly elects new Executive Board members
The EFORT General Assembly has announced the composition of the 2014/2015 Executive Board at the 15th EFORT Congress.
EFORT Executive Board 2014/2015
Mr A study scheduled to be presented on Friday, 6 June, which was designed to characterise the secretome of human mesenchymal stem cells in ischemic, hypoxic or normoxic conditions, will show that cells release mediators based on nutrient availability, regardless of the oxygen level.
"The take-home message of my study could be hypoxia promotes chemotactic and pro-angiogenic potential of human mesenchymal stem cells (hMSCs) secretome," Joseph Paquet, PhD, of Paris, said in an interview prior to the 15th EFORT Congress -a combined programme in partnership with the BOA.
Better understanding
According to Paquet, it was important to study whether the benefi ts of hMSCs can be conferred through transitory paracrine effects via all kinds of secreted chemical compounds since much about using these cells in regenerative medicine is still unknown. The investigators used MSCs from the bone marrow of fi ve patients undergoing orthopaedic procedures and exposed them to an ischemic environment of pO2=0.1%, serum deprived, an hypoxia environment of pO2=0.1%, 5g/L glucose, and a normoxic environment of pO2=21%. Hypoxia was sustained for 21 days using a hypoxic station (Biospherex; Lacona, N.Y., USA).
In the lab, when there is no chance for vascularisation and extremely low levels of oxygen, hMSCs die after 10 days, Paquet said.
"It is not so good. Therefore, we decided to focus on paracrine potential of mesenchymal stem cells in these conditions," he said.
Over 21 days Paquet and colleagues assessed various levels of mediators that are chemo-attractant, infl ammatory and immunomodulative using conditioned media or by seeding the cells on matrigel. In addition, they assessed how the secreted mediators functioned in vivo.
In vitro model
"By using an in vitro model of ischemia/hypoxia, we fi rst demonstrated that hMSC secretome is deeply affected, quantitatively and qualitatively, by the presence or no nutrients (i.e., glucose) under hypoxia," the investigators wrote in the abstract.
They further noted the mediators produced by the hMSCs in the hypoxic environment they looked at showed signs of selectivity.
"Immunomodulatives and infl ammatory mediators currently described to be secreted by hMSCs, under 'normoxic conditions, ' are not expressed and secretome profi le is focused on pro-angiogenic and chemo-attractive chemical compounds," they wrote.
Paquet said what is new or different about his study is "the conditions where we worked because many studies consider hypoxic conditions at 5% of oxygen or 2%, but what we did was to study it in pO2=0.1%. At 5% of oxygen the cells behave like normal hypoxic conditions. I have not seen any study with very low oxygen."
Paquet said his group is working with adipose stem cells to see if they behave similarly in these same conditions.
Paquet J. Paper #2279. Presented at: 15th EFORT Congress -a combined programme in partnership with the BOA; 4-6 June, 2014; London.
Source info:
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Researchers found patients younger than 50 years old had fewer complications and better survivorship at the 30-year follow-up when they first underwent high tibial osteotomy rather than unicompartmental or total knee arthroplasty as treatment for medial compartment osteoarthritis, based on results of a study scheduled to be presented on Friday, 6 June, at the 15th EFORT Congress -a combined programme in partnership with the BOA.
"The patients who fi rst had high tibial osteotomy were better than those we began with an arthroplasty in the longterm and the reason is when we began with high tibial osteotomy, there was only one revision or no revision," said Philippe Hernigou, MD, professor of orthopaedic surgery at CHU Henri Mondor, in Créteil, France, in an interview prior to the EFORT Congress. "When we fi rst began with total knee or unicompartmental arthroplasty, there were several revisions," said Hernigou, who is scheduled to present the study.
In the retrospective study, Hernigou and colleagues compared 218 knees in 116 men and 70 women. Mean age was 42 years when the patients underwent high tibial osteotomy (HTO), unicompart-mental knee arthroplasty (UKA) or total knee arthroplasty (TKA) between 1973 and 1982. There was a minimum follow-up of 30 years and maximum follow-up of 40 years. Patients underwent 138 HTOs, 30 UKAs and 50 TKAs in all.
Poor survival for arthroplasty
Amoung the 138 patients who underwent HTO fi rst, eight knees underwent no revisions. Thirty-nine knees underwent a repeat osteotomy, but did not undergo TKA, according to Hernigou.
Of the patients who underwent UKA or TKA fi rst, 44 knees required one revision TKA, 28 knees required two revisions and eight knees required three revisions and one amputation. Surgeons performed 204 revision arthroplasties in patients who underwent UKA or TKA fi rst, which were due to loose components (164), deep infection (8), instability (16) and patellar maltracking (14).
When done at 10 years, the survivorship of the first revision was 80% for HTO, 75% for UKA and 77% for TKA, Hernigou said. When the first revision was at 20 years, survivorship was 50% for HTO, 0% for UKA and 35% for TKA. When the first revision was done at 30 years, survivorship was 6% for HTO and 0% for both UKA and TKA.
For the second revision done at 20 years, survivorship was 100% for HTO, 40% for UKA and 65% for TKA, and for a second revision done at 30 years, survivorship was 100% for HTO, 0% for UKA and 35% for TKA.
Concerning repeat revisions, when three revisions were done by the 30year follow-up, survivorship was 50% for UKA and 70% for TKA, according to study results.
